My exact face when I came on to read about FX-322...
My exact face when I came on to read about FX-322...
I'm on the left-leaning socialist end of the spectrum, but that was a real clanger.privileged white person
Thanks for pointing it out. I agree it probably means nothing, but it's nice to see they believe in it enough to buy.Back to Frequency: New insider buying (worth about a million):
http://insiderbuyingselling.com/?t=FREQ
Don't think it's very relevant (just like much of the selling) but usually only the selling gets anxiety posted here.
Also interesting is that Christopher Loose (co-founder), didn't do his usual biweekly 4.5k share sell. He could still do it a day or two late, but to suddenly stop when another person who'd been selling bought 55k shares is a little interesting.Back to Frequency: New insider buying (worth about a million):
http://insiderbuyingselling.com/?t=FREQ
Don't think it's very relevant (just like much of the selling) but usually only the selling gets anxiety posted here.
I believe executive stockholders are back in a lock-out period due to the private placement, so they won't be able to dispose of their vested options for a certain period of time. Take a look at the 8-K submission related to the private placement.Also interesting is that Christopher Loose (co-founder), didn't do his usual biweekly 4.5k share sell. He could still do it a day or two late, but to suddenly stop when another person who'd been selling bought 55k shares is a little interesting.
The guy who bought had previously been selling.Also interesting is that Christopher Loose (co-founder), didn't do his usual biweekly 4.5k share sell. He could still do it a day or two late, but to suddenly stop when another person who'd been selling bought 55k shares is a little interesting.
Yeah mid/small cap volatility has probably been your friend this first half of 2020. FREQ is not immune from radical swings in this space.@Diesel
I have been buying and selling FREQ stock the last 2 months. I'm planning to eventually hold it for the long term though but I'm quite limited on money. Anyway, I've made over a thousand pounds so far, I buy under $20 or thereabouts and sell around $23 to $24. I reinvest all the initial cash so I can hold more stocks in the company.
I do plan to hold them before the results of the trial though. I guess then it'll shoot up or down depending how it goes?
Obviously my main hope this works goes beyond financial profit, thanks for the info on the insider trading - you beat me to it to update the forum.
Anyway, lots of momentum on the forums for traders on this stock.
All that is known so far is that Astellas will be handling European trials.Hello, do we know when the clinical trials will be done in Europe? And where?
To be fair to @Enclave, his point about minority groups typically having less disposable income than whites and therefore being disadvantaged by paid content would be somewhat valid if the content was only available at a cost indefinitely. However, as it is available for free next week, the point is moot. Maybe @Enclave missed that part in the video.{...] all I saw was a privileged white person...
I have just read that paper.Since results get asked about a lot, this document is probably the single best place to get Phase 1 results all in one place:
https://investors.frequencytx.com/static-files/6d161090-16f5-49f4-9606-8caceb5a88a1
It would have been helpful to show whether the 4/15 were part of the Mild or Moderate-Severe hearing loss patient group. Considering the ceiling effect encountered with the mild hearing loss patients... I suspect the 4 that saw the 10 dB improvement are the same 4 that they've continued to focus on throughout their presentation. So really, it's probably 4/6 with Moderate-Severe hearing loss saw a 10 dB improvement.I have just read that paper.
@FGG, I'd like to thank you for all information you bring to this community.
Just 4 out of 15 patients with 10 dB Improvement at 8000 Hz among those who received FX-322 is something (considering that there is nothing so far), but it is not an impressive result (considering this is an optimistic headline from the company).
Maybe, I'm pessimistic by nature.
Doubling word scores, however, is a monumental achievement. They are measuring up to 16000 Hz in this trial and I would be extremely surprised if they didn't get dramatic UHF audiogram results considering how unheard of the word score results are.I have just read that paper.
@FGG, I'd like to thank you for all information you bring to this community.
Just 4 out of 15 patients with 10 dB Improvement at 8000 Hz among those who received FX-322 is something (considering that there is nothing so far), but it is not an impressive result (considering this is an optimistic headline from the company).
Maybe, I'm pessimistic by nature.
The doubling word scores were pretty impressive.I have just read that paper.
@FGG, I'd like to thank you for all information you bring to this community.
Just 4 out of 15 patients with 10 dB Improvement at 8000 Hz among those who received FX-322 is something (considering that there is nothing so far), but it is not an impressive result (considering this is an optimistic headline from the company).
Maybe, I'm pessimistic by nature.
I think it could be the opposite, the less severely effected probably didn't "use up" the drug in terms of binding substrate further towards the base of the cochlea. But agree, that would be really useful information! Though that should become apparent with phase 2A results.It would have been helpful to show whether the 4/15 were part of the Mild or Moderate-Severe hearing loss patient group. Considering the ceiling effect encountered with the mild hearing loss patients... I suspect the 4 that saw the 10 dB improvement are the same 4 that they've continued to focus on throughout their presentation. So really, it's probably 4/6 with Moderate-Severe hearing loss saw a 10 dB improvement.
Also of importance is that of the 15 people who were treated, 8 got a low dose of FX-322, and 7 got a high dose (which is the regular dose for the Phase 2a trials). I've never seen it explicitly stated by Frequency, but many on this forum speculate that the 4 responders were in the group of 7 that got the high dose. Other important bits:It would have been helpful to show whether the 4/15 were part of the Mild or Moderate-Severe hearing loss patient group. Considering the ceiling effect encountered with the mild hearing loss patients... I suspect the 4 that saw the 10 dB improvement are the same 4 that they've continued to focus on throughout their presentation. So really, it's probably 4/6 with Moderate-Severe hearing loss saw a 10 dB improvement.
I didn't consider it in those terms. This is where I run out of "science" in understanding how the drug works.I think it could be the opposite, the less severely effected probably didn't "use up" the drug in terms of binding substrate further towards the base of the cochlea. But agree, that would be really useful information! Though that should become apparent with phase 2A results.
I think they already stated all four were moderate-severe.I think it could be the opposite, the less severely effected probably didn't "use up" the drug in terms of binding substrate further towards the base of the cochlea. But agree, that would be really useful information! Though that should become apparent with phase 2A results.
I think they already stated all four were moderate-severe.
Something that intrigues me is what the timeframe is for this drug to take effect and how long patients could expect to see improvements for.Also of importance is that of the 15 people who were treated, 8 got a low dose of FX-322, and 7 got a high dose (which is the regular dose for the Phase 2a trials). I've never seen it explicitly stated by Frequency, but many on this forum speculate that the 4 responders were in the group of 7 that got the high dose. Other important bits:
* Everyone saw word score improvements, it's just that only 4 met the threshold for statistically significant.
* People were continuing to improve, even at day 90 when the study ended (see slides 21 and 22).
Since the current study is measuring out to 210 days, it's possible we could see everyone who gets a single dose show statistical improvements.